BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12099326)

  • 1. ACE inhibitors as cardioprotective agents.
    Young JB
    Am J Manag Care; 2002 Jun; 8(9 Suppl):30-7. PubMed ID: 12099326
    [No Abstract]   [Full Text] [Related]  

  • 2. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the renin-angiotensin system in cardiovascular protection: Is it important to watch your C'ARB' intake?
    Strauss MH; Verma S
    Can J Cardiol; 2005 May; 21(7):577-80. PubMed ID: 15940355
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Weber MA; Giles TD
    Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.
    López-Sendón J; Swedberg K; McMurray J; Tamargo J; Maggioni AP; Dargie H; Tendera M; Waagstein F; Kjekshus J; Lechat P; Torp-Pedersen C;
    Eur Heart J; 2004 Aug; 25(16):1454-70. PubMed ID: 15302105
    [No Abstract]   [Full Text] [Related]  

  • 8. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
    Probstfield J
    J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849
    [No Abstract]   [Full Text] [Related]  

  • 9. [The renin-angiotensin-aldosterone system, angiotensin I converting enzyme, and the ACE-inhibitors. Historical perspective and recent findings].
    Gensini GF; Lippi D; Conti AA
    Recenti Prog Med; 2002 Oct; 93(10):544-53. PubMed ID: 12405014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Angiotensin receptor blocker often a valuable alternative to ACE inhibitors].
    Partanen J
    Duodecim; 2003; 119(13):1193-6. PubMed ID: 12908180
    [No Abstract]   [Full Text] [Related]  

  • 11. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
    Ram CV; Deedwania PC
    Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ACE-inhibitors: the indication spectrum grows wider].
    Fortschr Med Suppl; 1996; 178():1-10. PubMed ID: 9022411
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal medical management around the time of surgery.
    Voûte MT; Winkel TA; Poldermans D
    Heart; 2010 Nov; 96(22):1842-8. PubMed ID: 20965994
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.